Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-6209 capsules and HRS-2189 tablets, which will be conducted in conjunction with aromatase inhibitors for breast cancer treatment [1] Group 1: Regulatory Approval - The company and its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., have been granted the Clinical Trial Approval Notice for HRS-6209 and HRS-2189 [1] - The approval is based on the review under the Drug Administration Law of the People's Republic of China, confirming that the drugs meet the registration requirements [1] Group 2: Clinical Trial Details - The clinical trials for HRS-6209 will be conducted in combination with HRS-2189 and aromatase inhibitors specifically for breast cancer [1] - The acceptance date for the application was August 13, 2025, indicating a timeline for the development of these drugs [1]